On October 4, 2023 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that three abstracts have been accepted for poster presentation at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) in Boston on October 13, 2023 (Press release, Kura Oncology, OCT 4, 2023, View Source [SID1234635641]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to presenting the latest findings from our emerging next-generation farnesyl transferase inhibitor (FTI) program at this year’s AACR (Free AACR Whitepaper)-NCI-EORTC International Conference," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "These promising preclinical data further support the rationale for combining KO-2806 with distinct classes of targeted therapies, including tyrosine kinase inhibitors (TKIs), KRASG12C inhibitors and KRASG12D inhibitors. These findings illustrate the potential for FTIs to drive enhanced antitumor activity and address mechanisms of innate and adaptive resistance to targeted therapies."
Session titles and information for the three abstracts are listed below. Full abstract details will be available to registrants via the AACR (Free AACR Whitepaper) conference app on October 4, 2023 at 12:00 PM ET.
KO-2806, a next-generation farnesyltransferase inhibitor, potentiates the antitumor activity of cabozantinib in clear cell renal cell carcinoma models
Session Date and Time: Friday, October 13, 2023; 12:30 PM – 4:00 PM ET
Session and Location: Poster Session B, Level 2, Exhibit Hall D
Poster Number: B024
The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRASG12C inhibitor adagrasib in KRASG12C non-small cell lung carcinoma
Session Date and Time: Friday, October 13, 2023; 12:30 PM – 4:00 PM ET
Session and Location: Poster Session B, Level 2, Exhibit Hall D
Poster Number: B025
The next-generation farnesyltransferase inhibitor KO-2806 constrains compensatory signaling reactivation to deepen responses to KRASG12D inhibition
Session Date and Time: Friday, October 13, 2023; 12:30 PM – 4:00 PM ET
Session and Location: Poster Session B, Level 2, Exhibit Hall D
Poster Number: B023
Copies of the presentations will be available in the Posters and Presentations section on Kura’s website following presentation at the conference.